Supplemental Figure
1. Patient survival after starting cemiplimab immunotherapy for advanced
cSCC.
The overall patient
survival in the 4 patients who developed liver injury was not significantly
different versus those without liver injury. (p = 0.99 Kaplan‐Meier statistics).
Abbreviations: cSCC =
cutaneous squamous cell carcinoma
Supplemental Table 1.
Clinical characteristics and outcomes of solid organ transplants recipients
with cutaneous squamous cell carcinoma receiving cemiplimab monotherapy.
Abbreviations: YO =
year old; M = male, F = female; irAEs = immune related adverse events